Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study to Assess Biodistribution of 89Zr-CB307 in PSMA+ and PSMA- Tumour Lesions (A Sub-study of CBT307-1 Study - EUDRACT 2019-004584-46)

NCT05836623 is registered in ClinicalTrials.gov with Crescendo Biologics Ltd. as lead sponsor.

NCT NCT05836623
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05836623 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study to Assess Biodistribution of 89Zr-CB307 in PSMA+ and PSMA- Tumour Lesions (A Sub-study of CBT307-1 Study - EUDRACT 2019-004584-46)
Lead sponsor
Crescendo Biologics Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
December 20, 2022
Completion date
October 31, 2024
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced and/or metastatic solid tumours